1. Search Result
Search Result
Results for "

Epilepsy

" in MedChemExpress (MCE) Product Catalog:

105

Inhibitors & Agonists

4

Screening Libraries

2

Biochemical Assay Reagents

8

Peptides

1

Inhibitory Antibodies

9

Natural
Products

18

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1642

    Peganone

    Others Neurological Disease
    Ethotoin (Peganone) is an orally active anticonvulsant agent used in epilepsy research, Ethotoin is a hydantoin, similar to phenytoin .
    Ethotoin
  • HY-119810

    Ucb 44212

    Others Neurological Disease
    Seletracetam (Ucb 44212), as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy .
    Seletracetam
  • HY-149422

    Fluorescent Dye Neurological Disease
    NIR-FP is a near-infrared fluorescent probe with high sensitivity and selectivity for superoxide anion O 2-. O 2- is the main precursor of ROS, and ferroptosis-mediated epilepsy models can be dynamically tracked by detecting O 2-. Ferroptosis-mediated epilepsy models include: kainic acid (HY-N2309)-induced chronic epilepsy model, Pentylenetetrazole-induced acute epilepsy model, and pilocarpine (HY-B0726A)-induced epilepsy model .
    NIR-FP
  • HY-119915

    M-144; Themisone

    Others Neurological Disease
    Atrolactamide (M-144) is a potent anticonvulsant. Atrolactamide can be used for the research of epilepsy .
    Atrolactamide
  • HY-B1427

    Gamma-amino-beta-hydroxybutyric acid

    Endogenous Metabolite Neurological Disease
    Gamibetal is the gamma-amino-beta-hydroxybutyric acid. Gamibetal has the potential for the research of epilepsy .
    Gamibetal
  • HY-119810A

    Ucb 44212 lithium

    HIV Neurological Disease
    Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy .
    Seletracetam lithium
  • HY-119810B

    Ucb 44212 lithium bromide

    Others Neurological Disease
    Seletracetam (Ucb 44212) lithium bromide, an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy .
    Seletracetam lithium bromide
  • HY-105844

    BAX 422Z

    Others Neurological Disease
    Albutoin (BAX 422Z), an anticonvulsant agent, is a thiohydantoin derivative used for the research of grand mal epilepsies .
    Albutoin
  • HY-150539

    Calcium Channel Neurological Disease
    IAB15 is a potent T-type calcium channel inhibitor. IAB15 can be used for epilepsy research .
    IAB15
  • HY-110192
    ML 297
    1 Publications Verification

    VU 0456810; CID 56642816

    Potassium Channel Neurological Disease
    ML 297 (VU 0456810) is a potent and selective GIRK1/2 activator, with an EC50 of 0.16 μM. ML 297 is potential for the treatment of epilepsy .
    ML 297
  • HY-150541

    Calcium Channel Neurological Disease
    IAA65 is a potent T-type calcium channel inhibitor with a IC50 value of 18.9 µM. IAA65 can be used for epilepsy research .
    IAA65
  • HY-B1642S

    Peganone-d5

    Isotope-Labeled Compounds Neurological Disease
    Ethotoin-d5 is the deuterium labeled Ethotoin[1]. Ethotoin (Peganone) is an orally active anticonvulsant agent used in epilepsy research, Ethotoin is a hydantoin, similar to phenytoin[2].
    Ethotoin-d5
  • HY-137840

    Carboxypeptidase Cancer
    Hippuryl-L-phenylalanine is a substrate of carboxypeptidase. Carboxypeptidase is a protease enzyme that related with obesity, epilepsy and neurodegeneration. Hippuryl-L-phenylalanine can be used for the determination of carboxypeptidase activity .
    Hippuryl-L-phenylalanine
  • HY-B0339
    Primidone
    2 Publications Verification

    Sodium Channel Neurological Disease
    Primidone is a potent anticonvulsant agent of the barbiturate class. Primidone is a neuronal voltage-gated sodium channel (VGSC) blocker and can be used for the study of epilepsy, essential tremor, and Psychiatric disorders .
    Primidone
  • HY-105860

    BGG 492

    iGluR Neurological Disease
    Selurampanel (BGG 492) is an orally active and competitive AMPA receptor antagonist with an IC50 of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research .
    Selurampanel
  • HY-P1130

    Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide

    Neuropeptide Y Receptor Neurological Disease
    M871 (Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide) is a selective galanin receptor type 2 (GalR2) antagonist. M871 exhibits Ki values of 13.1 nM and 420 nM for GalR2 and GalR1, respectively. M871 can be used for research on GalR2-related diseases (such as epilepsy, pain) .
    M871
  • HY-14948

    RWJ-333369

    Others Neurological Disease
    Carisbamate (RWJ-333369) is an orally active neuromodulator. Carisbamate prevents the development and production of epilep-like discharges and has a neuroprotective effect after in vitro epilepticus-like injury. Carisbamate has good antiepileptic activity in genetic models of generalized and nonconvulsive epilepsy .
    Carisbamate
  • HY-B0246
    Carbamazepine
    5+ Cited Publications

    CBZ; NSC 169864

    Sodium Channel Autophagy Mitophagy Potassium Channel Calcium Channel HDAC Neurological Disease Cancer
    Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC50 of 131 μM. Carbamazepine blocks voltage gated Na +, Ca 2+, and K + channels, and is also a HDAC inhibitor (IC50: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain .
    Carbamazepine
  • HY-100783B

    (+)-Bicuculline methobromide; d-Bicuculline methobromide

    GABA Receptor Neurological Disease
    Bicuculline methobromide is a selective GABAA Receptor antagonist with an IC50 value of 3 μM. Bicuculline methobromide induces clonic tonic convulsions in mammals and can also be used to block Ca 2+ activated potassium channels. Bicuculline methobromide can be used in studies of epilepsy and other related psychiatric disorders .
    Bicuculline methobromide
  • HY-110178

    MAGL Inflammation/Immunology
    WWL123, a carbamate-based compound, is a potent and selective ABHD6 inhibitor. WWL123 can be used for research of inflammation, metabolic disorders (obesity and type II diabetes mellitus) and epilepsy .
    WWL123
  • HY-14232

    Calcium Channel Neurological Disease
    TTA-A8 (Compound 13) is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC50 value of 31.3 nM in the FLIPR depolarization assay. TTA-A8 possesses favorable pharmacokinetic properties, making it suitable for research on epilepsy and sleep .
    TTA-A8
  • HY-146100

    GABA Receptor Neurological Disease
    GABAA receptor agent 8 (compoud 5e) is a potent GABAA receptor positive modulator. GABAA receptor agent 8 shows anticonvulsant activity in vitro and in vivo with low neurotoxicity. GABAA receptor agent 8 has the potential for the research of epilepsy .
    GABAA receptor agent 8
  • HY-146099

    GABA Receptor Neurological Disease
    GABAA receptor agent 7 (compoud 5c) is a potent GABAA receptor positive modulator. GABAA receptor agent 7 shows anticonvulsant activity in vitro and in vivo with low neurotoxicity. GABAA receptor agent 7 has the potential for the research of epilepsy .
    GABAA receptor agent 7
  • HY-109123

    TAK-935; OV935

    Cytochrome P450 Neurological Disease
    Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, and orally active cholesterol 24-hydroxylase (CH24H) inhibitor. Soticlestat has the potential for epilepsy syndromes research .
    Soticlestat
  • HY-111038

    Coniferyl (E)-8-methyl-6-nonenoate

    TRP Channel Neurological Disease Inflammation/Immunology
    Capsiconiate (Coniferyl (E)-8-methyl-6-nonenoate) is a TRPV1 agonist (EC50= 3.2 μM). Capsiconiate can be used to study TRPV1-mediated diseases such as pain, inflammation, and epilepsy(EC50= 3.2 μM) .
    Capsiconiate
  • HY-152166

    Sodium Channel Neurological Disease
    NaV1.2/1.6 channel blocker-1 is a potent NaV1.2/1.6 channel blocker, with IC50s of 9.8 and 24.4 μM for rNaV1.6 and hNaV1.2, respectively. NaV1.2/1.6 channel blocker-1 can be used for the research of generalized epilepsy .
    NaV1.2/1.6 channel blocker-1
  • HY-P5857

    Micrurotoxin 2

    GABA Receptor Neurological Disease
    MmTx2 toxin is a GABAA receptor modulator that enhances GABAA receptor sensitivity to agonists. MmTx2 toxin can be obtained from venom of coral snake. MmTx2 toxin can be used in the study of neurological diseases such as epilepsy, schizophrenia and chronic pain .
    MmTx2 toxin
  • HY-N10368

    Parasite Infection Neurological Disease Inflammation/Immunology
    Shinjulactone M is a quassinoid isolated from various parts of Ailanthus species. Ailanthus, an important genus of the Simaroubaceae family, can be used as an febrifuge (antimalarial) and anthelmintic, and is given for the research of chronic bronchitis, epilepsy and asthma .
    Shinjulactone M
  • HY-105115

    ZK 112119

    GABA Receptor Neurological Disease
    Abecarnil (ZK 112119) is a ligand or a partial agonist for benzodiazepine (BZ) receptor. Abecarnil possesses anxiolytic and anticonvulsant properties. Abecarnil can act as a positive allosteric modulator of GABAA receptor. Abecarnil inhibits the binding of the BZ [3H]lormetazepam to rat cerebral cortex membranes, with an IC50 of 0.82 nM. Abecarnil can be used for epilepsy research .
    Abecarnil
  • HY-15078

    (R)-SPD502

    iGluR Neurological Disease
    NS1219 ((R)-SPD502) is the isomer of NS 1209 HY-15074. NS1209 is a selective AMPA receptor antagonist with neuroprotective activity. NS1209 can be used for the research of stroke, neuropathic pain and epilepsy .
    NS1219
  • HY-B1487

    Tricyclamol hydrochloride; (±)-Procyclidine hydrochloride

    iGluR mAChR Neurological Disease
    Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .
    Procyclidine hydrochloride
  • HY-123671

    Neuropeptide Y Receptor Neurological Disease
    CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice. Galanin receptors type 1 (GalR1) and/or type 2 (GalR2) represent unique pharmacological targets for the research of seizures and epilepsy .
    CYM2503
  • HY-B0495A

    LTG hydrate; BW430C hydrate

    Sodium Channel Autophagy Neurological Disease
    Lamotrigine hydrate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine hydrate selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine hydrate can be used for the research of epilepsy, focal seizure, et al .
    Lamotrigine hydrate
  • HY-B0495
    Lamotrigine
    5+ Cited Publications

    LTG; BW430C

    Sodium Channel Autophagy Neurological Disease
    Lamotrigine (BW430C) is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine selectively blocks voltage-gated Na + channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine can be used for the research of epilepsy, focal seizure, et al .
    Lamotrigine
  • HY-145761

    iGluR Neurological Disease
    AMPA-IN-1 is a potent inhibitor of AMPA receptor. AMPA receptors are receptors that are widely expressed in the brain, and play a central role in the regulation of fast excitatory synaptic transmission and synaptic plasticity. AMPA-IN-1 has the potential for the research of various central diseases including epilepsy (extracted from patent WO2017082288A1, compound 14) .
    AMPA-IN-1
  • HY-P1775

    EC 4.2.1.1

    Carbonic Anhydrase Neurological Disease Metabolic Disease Cancer
    Carbonic anhydrase, Bovine erythrocytes (EC 4.2.1.1) is ubiquitous zinc-containing metalloenzyme present in prokaryotes and eukaryotes. Carbonic anhydrase can catalyze reversible conversion of carbon dioxide to bicarbonate and protons. Carbonic anhydrase can be used for the research of cancer, glaucoma, obesity and epilepsy .

    Carbonic anhydrase, Bovine erythrocytes
  • HY-P5153

    μ-TRTX-Tp1a

    Sodium Channel Neurological Disease
    ProTx-III is a selective and potent inhibitor of voltage-gated sodium channel Nav1.7, with an IC50 of 2.1 nM. ProTx-III is a spider venom peptide isolated from the venom of the Peruvian green velvet tarantella. ProTx-III has a typical inhibitor cystine knot motif (ICK). ProTx-III is able to reverse the pain response. ProTx-III can be used to study diseases such as chronic pain, epilepsy, and arrhythmia .
    ProTx-III
  • HY-163390

    RIP kinase Necroptosis Inflammation/Immunology Cancer
    RIP1 kinase inhibitor 9 (compound SY-1) is a selective RIP kinase inhibitor. RIP1 kinase inhibitor 9 effectively suppresses the central inflammatory response induced by epilepsy. RIP1 kinase inhibitor 9 inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis in HT-29 cells with an EC50 of 7.04 nM .
    RIP1 kinase inhibitor 9
  • HY-148135

    Carbonic Anhydrase Neurological Disease
    hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and >50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
    hCAI/II-IN-6
  • HY-P3709

    p62 E1/E2/E3 Enzyme Neurological Disease
    TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .
    TRAF6 peptide
  • HY-P3709A

    p62 E1/E2/E3 Enzyme Neurological Disease
    TRAF6 peptide TFA is a specific TRAF6-p62 inhibitor. TRAF6 peptide TFA potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide TFA has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke .
    TRAF6 peptide TFA
  • HY-10955

    Calcium Channel Neurological Disease
    TTA-P1 is a potent state-independent compound inhibiting human T-type calcium channel. T-type calcium channels play a role in diverse physiological responses including neuronal burst firing, hormone secretion, and cell growth. TTA-P1 has the potential for the research of absence epilepsy .
    TTA-P1
  • HY-103308

    Potassium Channel Neurological Disease
    TRAM-39 is a selective blocker of intermediate conductance Ca2+-activated K+ (IKCa) channels. TRAM-39 inhibits KCa3.1 channel with an IC50 value of 60 nM. TRAM-39 can be used for the research of ataxia, epilepsy, memory disorders, schizophrenia and Parkinson’s disease .
    TRAM-39
  • HY-W050162

    TMCA

    GABA Receptor 5-HT Receptor Neurological Disease
    (E)-3,4,5-Trimethoxycinnamic acid (TMCA) is a cinnamic acid substituted by multi-methoxy groups. (E)-3,4,5-Trimethoxycinnamic acid is an orally active and potent GABAA/BZ receptor agonist. (E)-3,4,5-Trimethoxycinnamic exhibits favourable binding affinity to 5-HT2C and 5-HT1A receptor, with IC50 values of 2.5 and 7.6 μM, respectively. (E)-3,4,5-Trimethoxycinnamic acid shows anticonvulsant and sedative activity. (E)-3,4,5-Trimethoxycinnamic acid can be used for the research of insomnia, headache and epilepsy .
    (E)-3,4,5-Trimethoxycinnamic acid
  • HY-Y0669S

    Isotope-Labeled Compounds Endogenous Metabolite Bacterial
    Pipecolic acid-d9 is the deuterium labeled Pipecolic acid. Pipecolic acid, a metabolite of Lysine, is an important precursor of many useful microbial secondary metabolites. Pipecolic acid can be used as a diagnostic marker of Pyridoxine-dependent epilepsy[1][2].
    Pipecolic acid-d9
  • HY-19999A
    PF-CBP1 hydrochloride
    1 Publications Verification

    Epigenetic Reader Domain Histone Acetyltransferase Neurological Disease
    PF-CBP1 hydrochloride is a highly selective inhibitor of the CREB binding protein bromodomain (CBP BRD). PF-CBP1 inhibits CREBBP and EP300 bromodomains with IC50 of 125 nM and 363 nM respectively. PF-CBP1 hydrochloride reduces LPS-induced inflammatory cytokines expression (IL-1βIL-6 and IFN-β) in primary macrophages. PF-CBP1 hydrochloride also downregulates RGS4 expression cortical neurons and can be used for the research of neurological disorders, including epilepsy and parkinson's disease, et al .
    PF-CBP1 hydrochloride
  • HY-155811

    Others Neurological Disease
    DQP-997-74 (compound 2i) is a selective inhibitor of N-methyl-d-aspartate receptor (NMDAR), specifically targeting GluN2C/D (IC50: 0.069 μM and 0.035 μM), with blood-brain barrier penetrability. Where DQP refers to dihydroquinoline-pyrazoline. DQP-997-74 acts synergistically with the agonist glutamate to exhibit time-dependent enhanced potency in inhibiting hypersynchronous activity driven by high-frequency excitatory synaptic transmission. DQP-997-74 reduces the number of epileptogenesis in a murine model of tuberous sclerosis complex (TSC)-induced epilepsy. DQP-997-74 can be used for research on NMDAR-related neurological diseases .
    DQP-997-74
  • HY-111828
    TTA-A2
    1 Publications Verification

    Calcium Channel Neurological Disease
    TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy .
    TTA-A2
  • HY-160189

    GABA Receptor Neurological Disease
    3-Ethyl-3-methylthiolan-2-one is an antiepileptic agent that inhibits GABAA receptors .
    3-Ethyl-3-methylthiolan-2-one
  • HY-10585A
    Valproic acid sodium
    Maximum Cited Publications
    33 Publications Verification

    Sodium Valproate sodium

    Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite Infection Neurological Disease Metabolic Disease Cancer
    Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .
    Valproic acid sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: